200,000+ products from a single source!
sales@angenechem.com
Home > Pyridines > 452342-67-5
452342-67-5 | 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide
CAS No: 452342-67-5 Catalog No: AG00376S MDL No:MFCD16038936
Product Description
Catalog Number:
AG00376S
Chemical Name:
4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide
CAS Number:
452342-67-5
Molecular Formula:
C25H23N5O2
Molecular Weight:
425.4824
MDL Number:
MFCD16038936
IUPAC Name:
N-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1H-pyrazol-4-yl)pyridin-2-yl]benzamide
InChI:
InChI=1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)
InChI Key:
SAGZIBJAQGBRQA-UHFFFAOYSA-N
SMILES:
O=C(c1ccc(cc1)c1nccc(c1)c1c[nH]nc1c1ccccn1)NC1CCOCC1
UNII:
N14114957J
Properties
Complexity:
605
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
425.185g/mol
Formal Charge:
0
Heavy Atom Count:
32
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
425.492g/mol
Monoisotopic Mass:
425.185g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
92.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.7
Literature
| Title | Journal |
|---|---|
| Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. | PLoS neglected tropical diseases 20120601 |
| 2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling. | Bioorganic & medicinal chemistry letters 20110915 |
| Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. | American journal of physiology. Heart and circulatory physiology 20100501 |
| Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. | Arthritis and rheumatism 20100301 |
| The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. | Gastroenterology 20080601 |
| Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. | Kidney international 20080301 |
| Inhibition of ALK5 signaling induces physeal dysplasia in rats. | Toxicologic pathology 20070201 |
| Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. | Journal of medicinal chemistry 20060406 |
Related Products
© 2019 Angene International Limited. All rights Reserved.